The price of Macrogenics Inc (NASDAQ: MGNX) closed at $14.72 in the last session, down -1.60% from day before closing price of $14.96. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 808749 shares were traded. MGNX stock price reached its highest trading level at $15.25 during the session, while it also had its lowest trading level at $14.28.
Ratios:
We take a closer look at MGNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 04, 2024, Reiterated its Buy rating but revised its target price to $24 from $12 previously.
On February 14, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $12 to $14.
Citigroup Upgraded its Neutral to Buy on December 20, 2023, whereas the target price for the stock was revised from $7 to $13.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 06 ’24 when Peters Jeffrey Stuart sold 19,625 shares for $21.50 per share. The transaction valued at 421,938 led to the insider holds 8,895 shares of the business.
Risser Eric Blasius sold 41,159 shares of MGNX for $813,501 on Mar 04 ’24. The Chief Operating Officer now owns 38,900 shares after completing the transaction at $19.76 per share. On Mar 04 ’24, another insider, Karrels James, who serves as the SVP, CFO and Secretary of the company, sold 30,000 shares for $20.50 each. As a result, the insider received 615,000 and left with 171,452 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 919.00M and an Enterprise Value of 723.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.64 while its Price-to-Book (P/B) ratio in mrq is 5.99. Its current Enterprise Value per Revenue stands at 12.64 whereas that against EBITDA is 358.54.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $21.88, while it has fallen to a 52-week low of $4.29. The 50-Day Moving Average of the stock is 16.16, while the 200-Day Moving Average is calculated to be 8.72.
Shares Statistics:
According to the various share statistics, MGNX traded on average about 1.39M shares per day over the past 3-months and 1.37M shares per day over the past 10 days. A total of 62.07M shares are outstanding, with a floating share count of 58.56M. Insiders hold about 6.21% of the company’s shares, while institutions hold 95.43% stake in the company. Shares short for MGNX as of Mar 15, 2024 were 5.6M with a Short Ratio of 4.04, compared to 6.38M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.97% and a Short% of Float of 10.94%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.62 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.79, while EPS last year was -$0.61. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.42 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$1.76 and -$3.19 for the fiscal current year, implying an average EPS of -$2.55. EPS for the following year is -$1.02, with 7 analysts recommending between $3.35 and -$2.76.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $15.66M. It ranges from a high estimate of $30M to a low estimate of $8.92M. As of the current estimate, Macrogenics Inc’s year-ago sales were $24.5M, an estimated decrease of -36.10% from the year-ago figure.
A total of 10 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $125.7M, while the lowest revenue estimate was $35.9M, resulting in an average revenue estimate of $66.79M. In the same quarter a year ago, actual revenue was $58.75M, up 13.70% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $133.7M in the next fiscal year. The high estimate is $326.22M and the low estimate is $33.3M. The average revenue growth estimate for next year is up 100.20% from the average revenue estimate for this year.
